GRAIL filings document the public-company disclosures of a healthcare issuer developing and commercializing Galleri, a multi-cancer early detection test built on a targeted methylation-based platform. Its 8-K reports furnish operating and financial results, corporate presentations, clinical and regulatory updates, and other material events related to the company’s cancer detection business.
Regulatory filings also cover proxy governance, shareholder voting matters, board and leadership succession disclosures, emerging growth company status, and capital-structure activity. Recent records include securities purchase agreements, common stock and pre-funded warrant disclosures, resale registration-related materials, an at-the-market equity distribution agreement, and lease obligations, alongside exhibits and risk-oriented disclosures tied to GRAIL’s operations and financing needs.
GRAIL director Steven Mizell received 206 deferred stock units of common stock on January 15, 2026 as director compensation. These units were granted under the company’s deferred stock program and 2024 Incentive Award Plan in lieu of $20,164.38 of cash fees for his board service, using a price of $97.44 per share, which matched the closing market price on the grant date. The awards vest immediately upon grant, meaning they are fully earned right away. Following this grant, Mizell directly beneficially owns 36,675 shares of GRAIL common stock.
GRAIL, Inc. reported that it plans to present a corporate update and preliminary financial information for the quarter and year ended December 31, 2025 at the 2026 J.P. Morgan Healthcare Conference. The company states that the slide presentation to be used at the conference is being furnished as Exhibit 99.1 to this current report. The company clarifies that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, meaning it is not subject to certain liabilities under the Securities Exchange Act and will not be incorporated by reference into other SEC filings unless specifically referenced. The report is signed on behalf of GRAIL by its Chief Financial Officer, Aaron Freidin.
GRAIL, Inc.'s Chief Financial Officer reported an insider sale of company stock. On 12/03/2025, the reporting person sold 25,000 shares of GRAIL common stock in an open market transaction coded "S" (sale). The weighted average sale price was $99.1527 per share, with individual trades executed between $99.00 and $99.76.
After this transaction, the reporting person beneficially owned 259,077 shares of GRAIL common stock, held directly. The footnote explains that the reported price is an average across multiple trades and that detailed trade-level pricing information within the stated range is available upon request.
GRAIL, Inc. (GRAL) reported an insider tax-related stock sale by its Chief Financial Officer. On 11/17/2025, the CFO disposed of 1,697 shares of common stock in an automatic sell-to-cover transaction at a weighted average price of $79.2 per share. These sales were executed by a broker to cover withholding taxes due upon the vesting and delivery of an equity award, rather than as a discretionary open-market sale.
After this transaction and a small correction of 10 shares to fix a prior reporting error, the reporting person beneficially owns 284,077 shares of GRAIL common stock, including 641 shares acquired through the company’s employee stock purchase plan on November 14, 2025.
GRAIL, Inc. reported two capital markets updates. The company filed a prospectus supplement for the resale of 3,925,767 shares of common stock previously issued to selling stockholders, consisting of 1,927,194 shares and 1,998,573 shares issuable upon exercise of pre-funded warrants. These securities were issued under a securities purchase agreement dated October 18, 2025 and are covered by GRAIL’s Form S-3 shelf.
GRAIL also entered an Equity Distribution Agreement with Morgan Stanley and TD Securities to establish an at-the-market program allowing sales of up to $300,000,000 of common stock from time to time. Sales may be made in transactions permitted by Rule 415, with a commission of up to 3.0% of gross proceeds payable to the sales agents. Related legal opinions and the agreement were filed as exhibits.
GRAIL, Inc. launched an at‑the‑market offering of up to $300,000,000 in common stock under a prospectus supplement to its shelf registration. Sales may be made from time to time through Morgan Stanley & Co. LLC and TD Securities (USA) LLC as sales agents or principals in transactions deemed an “at the market offering” on Nasdaq or otherwise at market-related or negotiated prices.
The sales agents will earn up to 3.0% of the gross sales price per share. Proceeds will go to GRAIL, and the company currently intends to use the net proceeds to fund commercial activities and reimbursement efforts, as well as for working capital and other general corporate purposes.
GRAIL’s common stock trades on Nasdaq as “GRAL”; the last reported sale price was $83.20 per share on November 13, 2025. Shares outstanding were 36,160,998 as of September 30, 2025. Under the equity distribution agreement, the total number of shares sold pursuant to the program will not exceed 6,900,000.
GRAIL, Inc. filed a prospectus supplement for the resale of up to 3,925,767 shares of common stock by selling stockholders. The registration covers 1,927,194 outstanding common shares and 1,998,573 shares issuable upon exercise of pre-funded warrants.
The company is not selling shares and will not receive proceeds from holder sales; it would receive the nominal $0.001 per-share exercise price if pre-funded warrants are exercised for cash. Selling holders may use various methods of sale, including brokerage transactions, block trades, privately negotiated deals and short sales after the registration statement is declared effective.
Examples include Deep Track Biotechnology Master Fund, Ltd. 927,909 and Farallon affiliates 571,021. Shares outstanding were 38,981,593 as of October 31, 2025. GRAL trades on Nasdaq Global Select Market; the last reported sale price was $84.77 on November 12, 2025.
GRAIL, Inc. (GRAL) reported Q3 2025 results. Total revenue was $36,194 (thousands), up from $28,652 (thousands) a year ago, driven mainly by screening revenue of $32,807 (thousands). Net loss narrowed to $88,977 (thousands), or $2.46 per share, from $125,688 (thousands) a year earlier as operating expenses declined.
Cash and cash equivalents were $126,892 (thousands) and short‑term marketable securities were $413,238 (thousands) as of September 30, 2025. Year‑to‑date, operating cash use was $235,222 (thousands). Management states existing cash, cash equivalents, and short‑term marketable securities will be sufficient for at least the next 12 months. Total assets were $2,601,031 (thousands) with stockholders’ equity of $2,239,963 (thousands). As of November 10, 2025, common shares outstanding were 38,982,223.
GRAIL, Inc. entered into a Securities Purchase Agreement for a private placement of 4,639,543 shares of common stock (or pre-funded warrants with a $0.001 exercise price) at $70.05 per share, for approximate gross proceeds of $325.0 million. Closing is expected on October 21, 2025.
The pre-funded warrants are immediately exercisable and include a Beneficial Ownership Limitation of 4.99% or 9.99% (holder election), which may be increased upon 61 days’ notice up to 19.99%. GRAIL agreed to file a resale registration statement within 30 days after closing and use reasonable best efforts to obtain effectiveness within 60 days of filing or within 5 business days after an SEC no-review notice. The transaction is exempt under Section 4(a)(2) and Regulation D.
GRAIL, Inc. (GRAL) disclosed a routine director equity grant. On October 15, 2025, director William Chase received 275 deferred stock units in lieu of $20,794.52 of cash director fees, valued at $75.52 per share, the closing price that day. The awards vest immediately upon grant. After the transaction, his beneficial ownership was 36,590 shares, held directly.